Outstanding New Investigator Awards

About the Award

Several Outstanding New Investigators are recognized each year based on their contributions to the field of gene and cell therapy. Investigators from academia, research foundations, government, and industry are all eligible to be nominated for awards. Recipients of the Outstanding New Investigator Awards are celebrated at the ASGCT Annual Meeting every year. Each awardee will present a plenary lecture highlighting their scientific accomplishments that led to the award.

Criteria and Nominations

Any ASGCT member, other than a current officer or member of the Nomination and Awards Committee, is eligible. Nomination letters must be 500 words or fewer and be submitted by two ASGCT members. Nominees will be notified and required to provide a CV or NIH bio-sketch.

To be eligible, nominees must be:

  1. Independent investigators conducting original research in basic science, technology development, and/or clinical translation in the field of gene and cell therapy;

  2. Ten or fewer years out from their first active independent investigator position;

  3. Members in good standing of the Society;

  4. Nominated by two (or more) ASGCT members in good standing; and 

  5. Available to give a presentation of their work at the next ASGCT Annual Meeting.

Nominations for the 2024 Annual Meeting are open through Jan. 31, 2024. Please send your nominations to awards@asgct.org.



Maksim “Max” Mamonkin, PhD
Justin Eyquem, PhD
Shondra Pruett-Miller, PhD
Manuela Corti, PhD 


Lindsey George, MD, Childen's Hospital of Philadelphia
Matthew Hirsch, PhD, University of North Carolina
Morgan Maeder, PhD, Chroma Medicine
Christopher Peterson, PhD, Fred Hutchinson Cancer Center


Natalia Gomez-Ospina, MD, PhD, Stanford University
Benjamin Kleinstiver, PhD, Massachusetts General Hospital
Marcela Maus, MD, PhD, Massachusetts General Hospital
Annarita Miccio, PhD, Imagine Institute

Daniel Bauer, M.D., Ph.D., Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School
Gene Editing for Autologous Hematopoietic Stem Cell Therapy

James Dahlman, Ph.D., Georgia Tech and Emory University
Identifying LNPs with Novel Tropism by Testing Thousands in Vivo Using DNA Barcodes

Viviana Gradinaru, Ph.D., California Institute of Technology (Caltech)
Systemic Gene Delivery to the Central and Peripheral Nervous Systems and Applications to Neurodegeneration

Shengdar Tsai, Ph.D., St. Jude Children's Research Hospital
Understanding and Improving Genome Editors for Therapeutics

Steven J. Gray, Ph.D., University of Texas Southwestern Medical Center, Dallas TX
On the Brink of a Treatment Revolution for Inherited Pediatric Neurological Diseases

Anna Kajaste-Rudnitski, Ph.D., San Raffaele Telethon Institute for Gene Therapy, Milano Italy
Dissecting and Overcoming Innate Immune Barriers for Therapeutically Efficient Hematopoietic Stem Cell Gene Engineering

Luca Biasco, Ph.D., Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston MA
Clonal Tracking of Genetically Engineered Hematopoietic Cells in Humans

Luk Vandenberghe, Ph.D., Grousbeck Gene Therapy Center, Boston, MA
On the Shoulders of Giants: Building Vectors and Gene Therapies

James Kochenderfer, M.D., National Cancer Institute
Chimeric Antigen Receptor T-cell Therapies for Hematologic Malignancies

Lili Yang. Ph.D., University of California Los Angeles
Stem Cell-Engineered T Cell Immunotherapy for Cancer

Jordan Green, Ph.D., Johns Hopkins University
Polymeric Nanoparticles for Gene and Cell Therapy to Treat Cancer

Marcin Kortylewski, Ph.D. - City of Hope Comprehensive Cancer Center
Eliminating Tumor Immune Defenses using Oligonucleotide Therapeutics

Eirini P. Papapetrou, M.D., Ph.D. - Icahn School of Medicine at Mount Sinai
Genetic Engineering of Human Induced Pluripotent Stem Cells for Regenerative Medicine and Disease Modeling

Junghae Suh, Ph.D. - Rice University
Design of Biocomputing Viruses for Controlled Gene Delivery

Jennifer E. Adair, Ph.D., Fred Hutchinson Cancer Research Center
Found in Translation: Informed Development of Next-Generation Blood Stem Cell Gene Therapy

Ana Buj Bello, M.D., Ph.D., Genethon
Towards a Gene Therapy for Myotubular Myopathy

Dirk Grimm, Ph.D., University of Heidelberg
Small Viruses + Tiny RNAs = A Giant Toolbox for Gene and Cell Therapy

Eugenio Montini, Ph.D., San Raffaele Telethon Institute for Gene Therapy
Genetic Engineering of Somatic Cells by Viral/Vector Integrations in Gene Therapy and HIV-1 Infection

Brian D. Brown, Ph.D., Mt. Sinai School of Medicine
Dangerous Liaisons: Gene Transfer, microRNA, and the Immune System

Charles A. Gersbach, Ph.D., Duke University
Targeted Gene Correction and Regulation with Genome Engineering Technologies

Scott Q. Harper, Ph.D., Ohio State University & Nationwide Children's Hospital
Translating Facioscapulohumeral Muscular Dystrophy (FSHD)

Daniel J. Powell, Jr., Ph.D., University of Pennsylvania
Innovative Approaches to Adoptive T cell Therapy of Cancer

Aravind Asokan, Ph.D., University of North Carolina at Chapel Hill
A Sweet Side to AAV Biology

Paloma H. Giangrande, Ph.D., University of Iowa
Targeted-Image Guided RNA (TIGR) Therapies

Michael A. Laflamme, M.D., Ph.D., University of Washington
Cardiac Repair with Human Pluripotent Stem Cells

Ann M. Leen, Ph.D., Baylor College of Medicine - CAGT
T cell Therapy for Viruses and Cancer

Nicola Brunetti-Pierri,M.D., Telethon Institute of Genetics and Medicine, Napoli, Italy
Helper-Dependent Adenoviral Vectors for Hepatocyte Gene Therapy

Marco A. Passini, Ph.D., Genzyme - A Sanofi Company, Framingham, MA
Gene and Antisense Therapies for Neurodegenerative Disorders

Theresa M. Reineke, Ph.D., University of Minnesota
Design and Discovery of Glycopolymer Vehicles for the Delivery of Nucleic Acids

Benjamin R. tenOever, Ph.D., Mount Sinai School of Medicine
Harnessing the Power of Small RNAs in Vector-Mediated Therapeutics

Hiroyuki Nakai, M.D., Ph.D., University of Pittsburgh School of Medicine, Pittsburgh, PA
In Vivo Viral Genome and Capsid Biology of Recombinant AAV Vectors

Miguel Sena-Esteves, Ph.D., University of Massachusetts Medical School, Worcester, MA
AAV-Mediated Gene Therapy for Neuro-Metabolic Diseases and Brain Tumors

Qizhen Shi, M.D., Ph.D., Medical College of Wisconsin, Milwaukee, WI
Targeting Factor VIII (FVIII) Expression to Platelets for Gene Therapy of Hemophilia A with Inhibitors

Alessandra Biffi, M.D., San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
Rendering Hematopoietic Stem Cell Transplantation Efficacious for the Treatment of Lysosomal Disorders

Kevin V. Morris, Ph.D., Scripps Research Institute, La Jolla, CA
Utilizing the Endogenous Long Non-Coding RNA Pathway in Human Cells to Transcriptionally Modulate Gene Expression

Bakhos A. Tannous, Ph.D., Massachusetts General Hospital, Charlestown, MA
Ex-Vivo Monitoring of In Vivo Gene and Cell Therapy

Charles P. Venditti, M.D., Ph.D., National Human Genome Research Institute, Bethesda, MD
Gene Therapy for Methylmalonic Acidemia (MMA)

Renier J. Brentjens, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, New York, NY
Treatment of B-cell Malignancies with CD19 Targeted T-cells

Barbara Savoldo, M.D., Ph.D., Baylor College of Medicine, Houston, TX
Improving T Cell Based Therapies

Tatiana Segura, Ph.D., University of California-Los Angeles, Los Angeles, CA
Gene Delivery In Three Dimensions

Karen S. Aboody, M.D., City of Hope National Medical Center, Duarte CA
Stem Cell-Mediated Cancer Therapy: A Tumor-Selective Gene Delivery Approach

Maciej S. Lesniak, M.D., FACS, The University of Chicago, Chicago, IL
Adenoviral Virotherapy for Malignant Brain Tumors

Dmitry M. Shayakhmetov, Ph.D., University of Washington, Seattle, WA
Adenovirus-Host Interplay and the Development of Efficient Vectors for Gene Therapy

Gianpietro Dotti, M.D., Baylor College of Medicine, Houston, TX
Genetic Modifications of T Cells for Adoptive Immunotherapy in Cancer Patients

Akseli E. Hemminki, M.D., Ph.D., University of Helsinki, Helsinki, Finland
Oncolytic Adenoviruses for Killing of Cancer Initiating Cells

Philip Ng, Ph.D., Baylor College of Medicine, Houston, TX
Gene Therapy with Helper-Dependant Adenoviral Vectors

Derek Persons, M.D., Ph.D., St. Jude Children’s Research Hospital, Memphis, TN
Progress Toward Safe and Effective Gene Therapy for β-Thalassemia and Sickle Cell Disease

Alberto Auricchio, M.D., Telethon Institute of Genetics & Medicine, Napoli, Italy
AAV Serotypes for Gene Therapy of Inherited Human Diseases

Dongsheng Duan, Ph.D., University of Missouri School of Medicine, Columbia, MO
Pushing the Limit: Making a Small Virus to Work for a Large Gene

Salima Hacein-Bey Abina, Ph.D., INSERM U 429, Paris, France
Gene Therapy for Severe Combined Immunodeficiency X1

Punam Malik, M.D., Children’s Hospital Los Angeles, Los Angeles, CA
Gene Therapy for Red Blood Cell Disorders

Chiara Bonini, M.D., Fondazione Centro S. Raffaele Del Monte Tabor, Milan, Italy
Gene Transfer into Peripheral Blood T Lymphocytes: Clinical Benefits and Safety Profile

Michael Kaplitt, M.D., Ph.D., Weill Medical College of Cornell University, New York, NY
Development of Human Gene Therapy for Neurodegenerative Disorders

Michael A. Barry, Ph.D., Baylor College of Medicine, Houston, TX
Cell-Targeting Technologies for Gene Therapy

Laurence JN Cooper, M.D., Ph.D., City of Hope National Medical Center, Duarte, CA
T-cell Therapy for Malignant B Cells

Matthew Weitzman, Ph.D., Salk Institute, La Jolla, CA
Lessons from the Battleground of Virus-Host Interactions

Alessandro Aiuti, M.D., Ph.D., Fondazione Centro San Raffaele, Milan, Italy
Gene Therapy for ADA-Deficient SCID

Roland W. Herzog, Ph.D., Children’s Hospital of Philadelphia, Philadelphia, PA
Immunology of Factor IX Gene Transfer

Christof von Kalle, M.D., Cincinnati Children’s Hospital, Cincinnati, OH
Vector Insertion in Gene Modified Human Hematopoiesis


Register for the ASGCT Policy Summit

September 23-24, 2024 | Washington, D.C.